Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biological testing technologist Luminex (LMNX) has received an alarming one-star ranking.
With that in mind, let's take a closer look at Luminex and see what CAPS investors are saying about the stock right now.
Luminex facts
|
Headquarters (founded) |
Austin, Texas (1995) |
|
Market Cap |
$730.6 million |
|
Industry |
Life sciences tools and services |
|
Trailing-12-Month Revenue |
$202.6 million |
|
Management |
CEO Patrick Balthrop Sr. (since 2004) |
|
Return on Equity (average, past 3 years) |
4.4% |
|
Cash/Debt |
$56.4 million / $2.8 million |
|
Competitors |
Affymetrix |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 14% of the 106 members who have rated Luminex believe the stock will underperform the S&P 500 going forward.
Earlier this week, one of those bears, All-Star bclan13, succinctly summed up the bear case for our community:
Other technologies are coming in and taking away more and more of where Luminex's performance envelope has a competitive advantage (lab geeks' "mid-plex"). I see particular pressures in genetic disease testing. ... Longer term, there is a stable business for Luminex in [Human Leukocyte Antigens ] testing (particularly the protein tests) but this is not going to provide double digit growth forever -- a requirement of a company with this kind of valuation.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
